

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

**THERAPEUTIC AND DIAGNOSTIC METHODS AND COMPOSITIONS
BASED ON NOTCH PROTEINS AND NUCLEIC ACIDS**

TABLE OF CONTENTS

	<u>Page</u>
1. INTRODUCTION	1
2. BACKGROUND OF THE INVENTION	1
2.1. THE NOTCH GENE AND PROTEIN	1
2.2. CANCER	4
3. SUMMARY OF THE INVENTION	4
3.1. DEFINITIONS	6
4. DESCRIPTION OF THE FIGURES	6
5. DETAILED DESCRIPTION OF THE INVENTION	11
5.1. THERAPEUTIC USES	13
5.1.1. MALIGNANCIES	18
5.1.2. NERVOUS SYSTEM DISORDERS	20
5.1.3. TISSUE REPAIR AND REGENERATION	23
5.2. PROPHYLACTIC USES	23
5.2.1. MALIGNANCIES	23
5.2.2. OTHER DISORDERS	26
5.3. DEMONSTRATION OF THERAPEUTIC OR PROPHYLACTIC UTILITY	26

	5.4.	THERAPEUTIC/PROPHYLACTIC ADMINISTRATION AND COMPOSITIONS	26
	5.5.	ANTISENSE REGULATION OF NOTCH EXPRESSION	30
	5.5.1.	NOTCH ANTISENSE NUCLEIC ACIDS	32
5	5.5.2.	THERAPEUTIC UTILITY OF NOTCH ANTISENSE NUCLEIC ACIDS	35
	5.6.	DIAGNOSTIC UTILITY	36
	5.7.	NOTCH NUCLEIC ACIDS	38
10	5.8.	RECOMBINANT PRODUCTION OF PROTEIN THERAPEUTICS	43
	5.8.1.	IDENTIFICATION AND PURIFICATION OF THE EXPRESSED GENE PRODUCT	47
	5.9.	DERIVATIVES AND ANALOGS OF NOTCH AND OTHER TOPORYTHMIC PROTEINS	48
15	5.9.1.	DERIVATIVES OF NOTCH CONTAINING ONE OR MORE DOMAINS OF THE PROTEIN	52
20	5.9.2.	DERIVATIVES OF NOTCH OR OTHER TOPORYTHMIC PROTEINS THAT MEDIATE BINDING TO TOPORYTHMIC PROTEIN DOMAINS, AND INHIBITORS THEREOF	52
	5.10.	ASSAYS OF NOTCH PROTEINS, DERIVATIVES AND ANALOGS	55
	5.11.	ANTIBODIES TO NOTCH PROTEINS, DERIVATIVES AND ANALOGS	56
25	6.	DOMAINS OF NOTCH MEDIATE BINDING WITH DELTA	57
	6.1.	EXPERIMENTAL PROCEDURES	58
	6.1.1.	EXPRESSION CONSTRUCTS	58
30	6.1.2.	ANTIBODY PREPARATION	59
	6.1.3.	CELL CULTURE AND TRANSFECTION	60

	6.1.4.	AGGREGATION ASSAYS	60
	6.1.5.	IMMUNOFLUORESCENCE	61
	6.1.6.	CELL LYSATES, IMMUNOPRECIPITATIONS, AND WESTERN BLOTS	62
5	6.2.	RESULTS	63
	6.2.1.	THE EXPRESSION OF NOTCH AND DELTA IN CULTURED CELLS	63
	6.2.2.	CELLS THAT EXPRESS NOTCH AND DELTA AGGREGATE	63
10	6.2.3.	NOTCH-DELTA-MEDIATED AGGREGATION IS CALCIUM DEPENDENT	65
	6.2.4.	NOTCH AND DELTA INTERACT WITHIN A SINGLE CELL	65
15	6.2.5.	INTERACTIONS WITH DELTA DO NOT REQUIRE THE INTRACELLULAR DOMAIN OF NOTCH	66
	6.2.6.	NOTCH AND DELTA FORM DETERGENT-SOLUBLE INTERMOLECULAR COMPLEXES	66
20	6.3.	DISCUSSION	67
7.		EGF REPEATS 11 AND 12 OF NOTCH ARE REQUIRED AND SUFFICIENT FOR NOTCH-DELTA-MEDIATED AGGREGATION	67
25	7.1.	EXPERIMENTAL PROCEDURES	68
	7.1.1.	EXPRESSION CONSTRUCTS	68
	7.1.2.	CELL CULTURE AND TRANSFECTION	68
	7.1.3.	AGGREGATION ASSAYS AND IMMUNOFLUORESCENCE	68
30	7.2.	RESULTS	69

5	7.2.1.	EGF REPEATS 11 AND 12 OF NOTCH ARE REQUIRED FOR NOTCH-DELTA MEDIATED AGGREGATION	69
	7.2.2.	EGF REPEATS 11 AND 12 OF NOTCH ARE SUFFICIENT FOR NOTCH-DELTA MEDIATED AGGREGATION	72
	7.2.3.	EGF REPEATS 11 AND 12 OF NOTCH MAINTAIN THE CALCIUM DEPENDENCE OF NOTCH-DELTA MEDIATED AGGREGATION	73
10	7.2.4.	THE DELTA BINDING FUNCTION OF EGF REPEATS 11 AND 12 OF NOTCH IS CONSERVED IN THE XENOPUS HOMOLOG OF NOTCH	73
	7.3.	DISCUSSION	74
15	8.	SEQUENCES WHICH MEDIATE NOTCH-SERRATE INTERACTIONS	75
	9.	THE CLONING, SEQUENCING, AND EXPRESSION OF HUMAN NOTCH	77
	9.1.	ISOLATION AND SEQUENCING OF HUMAN NOTCH	77
	9.2.	EXPRESSION OF HUMAN NOTCH	81
20	10.	NOTCH EXPRESSION IN NORMAL AND MALIGNANT CELLS	83
	10.1.	EXPRESSION OF HUMAN NOTCH PROTEIN IS INCREASED IN VARIOUS MALIGNANCIES	85
25	11.	DEPOSIT OF MICROORGANISMS	88